Abbott receives fda approval for its spinal cord stimulation systems to treat chronic back pain in people who have limited surgical options

Fda approval was backed by abbott's distinct study, the largest randomized controlled trial for spinal cord stimulation (scs) in people with chronic back pain when surgery is not an option results for the first 200 patients demonstrated that people who used the company's scs products experienced significant relief and improvements in pain, function, quality of life and psychological status1,2 prior to enrollment in the study, participants suffered from severe, disabling chronic back pain for an average of 12.8 years2 abbott park, ill., may 16, 2023 /prnewswire/ -- abbott (nyse: abt) announced today that the u.s. food and drug administration (fda) has approved its spinal cord stimulation (scs) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
ABT Ratings Summary
ABT Quant Ranking